Sarah Cannon Docs
@SarahCannonDocs
A leading oncology research organization conducting community-based clinical trials.
SCRI is transforming cancer care through groundbreaking trials at 250 locations in 24 states. Join us in advancing therapies and offering hope. Watch how we collaborate to make a difference. #CancerResearch #ClinicalTrials #NewHope #SCRI scri.com
Thank you, #ASCO25! We’re grateful to our presenters, panelists, and the entire ASCO community for an inspiring week of innovation and collaboration. Here’s to advancing therapies for patients —together. Until next year! #SCRI #CancerResearch #OncologyLeadership #ThankYouASCO
Tomorrow, SCRI's Dr. Yardley will join @industrydive in a State of Oncology Research Virtual Event. Join her June 5, 1PM ET. dive.pub/43zAmrB #CancerNews #OncologyResearch #SCRI #BreastCancerNews
Dr. Meredith McKean delivers her oral presentation on Novel Targets in #Melanoma Treatment at #ASCO2025
Dr. @VivekSubbiah shared final ARROW trial results on a developmental therapy for RET fusion-positive solid tumors at #ASCO25 yesterday. Thank you Dr. Subbiah for an insightful session on efficacy and safety!
Dr. Cloven shares her #ASCO25 poster on “Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.”
Happening now at #ASCO25! Dr. Naqash serves as chair during the Oral Abstract Session: Lung Cancer-Non- Small Cell Local-Regional/ Small Cell/ Other Thoracic Cancers session.
New data from the AIM-HIGH trial presented by Dr. @DavidRSpigel at #ASCO25 shows a 78% relative reduction in recurrence or death with adjuvant chemo for high-risk early-stage #NSCLC patients, identified via a 14-gene molecular assay. Watch interview here: ascopost.com/videos/2025-as…
📷 from #ASCO2025 where @SarahCannonDocs, @TheUSONetwork and @OntadaOncology are presenting a combined 170 abstracts on their latest research and innovations — showcasing their commitment to always advancing cancer research and care. Together, #CancerDoesntStandAChance.
Come meet SCRI expert, @ErikaHamilton9 at #ASCO25 booth 27022, now!
🚨 LIVE from #ASCO25 🚨 Dr. @ErikaHamilton9 presents first-in-human data on Emi-Le (B7-H4 ADC) in solid tumors. 🔹 ORR: 31% in B7-H4 high 🔹 ORR: 44% w/ ≤4 prior lines 🔹 ACC-I: 55.6% ORR Promising activity + tolerability in mBC, OC, EC & ACC-I. #SCRI #ADC #Oncology
We look forward to seeing more of you on day four of the #ASCO25 Annual Meeting. Stop by both #27022 to meet experts from across the network, from 9:45am-2:00pm. #CancerResearch uberflip.scri.com/i/1535506-meet…
Live from #ASCO25, Dr. @DavidRSpigel breaks down AIM-HIGH findings on a 14-gene assay guiding chemo decisions in early-stage #NSCLC, with a nearly 80% reduction in recurrence or death for high-risk patients. Watch his interview in @OncLive here: onclive.com/view/dr-spigel…
Dr. Melissa Johnson tackled how community oncology can deliver cutting-edge lung cancer therapies: 🔹 Not all bispecifics need inpatient care 🔹 Tarlatamab = outpatient-friendly 🔹 Innovative care models = better access #LungCancer #Immunotherapy #SCRI #ASCO25
Honoring a legacy in oncology! Dr. @Howard A. Burris III now has a Conquer Cancer Young Investigator Award in his name, recognizing his impact on cancer research. Congrats to inaugural recipient Dr. Allison Taylor! 🔗 scri.com/leadership/?co… #Oncology #CancerResearch #ASCO
At #ASCO25, Dr. Naqash explores the promise & challenges of bispecific T-cell engagers (BiTEs) in lung cancer & beyond: ✅ Tarlatamab earns FDA nod for SCLC ⚠️ CRS & ICANS toxicity management is key 🎯 DLL3 & other targets may expand BiTE reach #Immunotherapy #LungCancer
Meet the experts from Sarah Cannon Docs at the 2025 ASCO Annual Meeting! Visit booth #27022 to connect with leaders from across our organization and discover the latest in oncology research. uberflip.scri.com/i/1535506-meet…?
To all the fighters, heroes, mothers, grandmothers, friends, sons, coworkers, golf partners, sisters, bakers, neighbors and many more, happy National Cancer Survivors Day! Today, and every day we celebrate you. #NationalCancerSurvivorsDay scri.com/patients/
At #ASCO25, Dr. @ErikaHamilton9 presented Phase 3 VERITAC-2 results: 🧬 Vedegestrant (first PROTAC ER degrader) showed: ✅ Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC) ✅ Favorable safety (<5% AEs led to dose changes) ⏳ OS data maturing A promising new option!
SCRI patient, Jimi, shares his first-hand experience with sickle cell disease in a powerful ASCO/AACR Joint Session. #GeneTherapy #ASCOAACR #SCD #PrecisionMedicine #ASCO25
Dr. @hfrangoul takes the stage in the ASCO/AACR Joint Session: "Established Gene Therapy Options in the Clinic" 🧬 🔬 Exploring real-world gene therapy: successes, challenges & equitable access. #GeneTherapy #ASCOAACR #PrecisionMedicine #ASCO2025
